Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(4):275-279
DOI: 10.5428/pcar20190410
Efficacy of different doses of calf pulmonary surfactant in the treatment of neonatal respiratory distress syndrome:a meta analysis
1. TIAN Jing1(1.Department of Neonatology,Affiliated Hospital of Zhengzhou University/Nanyang Central Hospital,Henan Nanyang 473000,China 980663760@qq.com)
2. ZHANG Huanxin1(1.Department of Neonatology,Affiliated Hospital of Zhengzhou University/Nanyang Central Hospital,Henan Nanyang 473000,China )
3. TIAN Jinhui2(2.Evidence-based Medical Center,Lanzhou University, Lanzhou 730000,China )
4. ZHANG Peng1(1.Department of Neonatology,Affiliated Hospital of Zhengzhou University/Nanyang Central Hospital,Henan Nanyang 473000,China )
5. LI Lun3(3.Department of Breast Surgery,Fudan University Shanghai Cancer Center,Shanghai 200032,China guo19880101@163.com)
ABSTRACT  Objective: To systematically evaluate the safety and efficacy of different doses of calf pulmonary surfactant(CPS) in the treatment of neonatal respiratory distress syndrome(NRDS).Methods: All the related literature was retrieved from the databases of Chinese National Knowledge Infrastructure(CNKI),China Science and Technology Journal Database(VIP),Wanfang Data,Google Scholar,Pubmed,Cochrane Library,Embase from the inception to August 2017.The randomized controlled trails(RCTs) about the application of different doses of CPS in the treatment of NRDS were collected for the study.Meta analysis was performed using RevMan 5.2 software.Results: A total of 6 RCTs were included,encompassing 533 patients.Meta analysis showed that compared with 70 mg/kg CPS,the application of 100 mg/kg CPS could more effectively decrease the arterial partial pressure of carbon dioxide(PaCO2) [OR=-3.21,95%CI(-5.01,-1.41),P=0.000 5],increase arterial partial pressure of oxygen[OR=5.79,95%CI(4.05, 7.52),P<0.000 01] and pH value[OR=0.03,95%CI(0.00,0.05),P=0.02],reduce the time of assisted ventilation[OR=-0.64, 95%CI(-1.30,0.10),P=0.02],hospitalization time[OR=-2.31,95%CI(-3.94,-0.67),P=0.006],oxygen therapy time[OR=-1.40,95%CI(-2.13,-0.66),P=0.02] and medication time as well [OR=-0.27,95%CI(-0.38,-0.16),P<0.000 01].Compared with 40 mg/kg CPS,the application of 70 mg/kg CPS in the treatment of NRDS could also more effectively decrease PaCO2[OR=-2.62, 95%CI(-4.88,-0.35),P=0.02] and oxygenation index[OR=-1.82, 95%CI(-2.67,0.97),P<0.000 1],promote chest radiography improvement[OR=-0.20,95%CI(-0.39,-0.01),P=0.04],shorten the time of assisted ventilation[OR=-0.96,95%CI(-1.48,-0.45),P=0.000 2],oxygen therapy time[OR=-3.50,95%CI(-4.20,-2.80),P<0.000 01] and hospitalization time[OR=-2.35,95%CI(-3.55, -1.14),P=0.000 1] and decrease medication times[OR=-0.23,95%CI(-0.39,-0.07),P=0.000 5].There were no significant differences in cure rates,treatment costs and complication rates after treatment with 40,70,100 mg/kg CPS.Conclusion: Current evidence indicated that compared with 40 and 70 mg/kg CPS,the application of 100 mg/kg CPS in the treatment of NRDS was obviously more efficient.
Welcome to PCAR! You are the number 70 reader of this article!
Please cite this article as:
TIAN Jing1,ZHANG Huanxin1,TIAN Jinhui2,ZHANG Peng1,LI Lun3,. Efficacy of different doses of calf pulmonary surfactant in the treatment of neonatal respiratory distress syndrome:a meta analysis[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(4): 275-279.
References:
1. The Collaborative Group for Calsurf Study.Different doses of calf pulmonary surfactant in treatment of respiratory distress syndrom in preterm infants:a multicentered randomized controlled trial in China[J].Chin J Perinat Med,2017,20(4):260-267.In Chinese with English abstract.
2. ZHANG Jing,ZHANG Huanxin,WANG Jing.Clinical observation of different doses of calf pulmonary surfactant combined with nasal intermittent positive pressure ventilation in the treatment of neonatal respiratory distress syndrome[J].China Pharmacy,2016,27(35):4985-4987.In Chinese with English abstract.
3. LIAO Lingfan,GONG Hua,YI Ming,et al.Difference of multi-center controlled clinical efficacy in treatment of neonatal respiratory distress syndrome with different initial doses of pulmonary surfactant[J].Acta Acad Med Mil Tertiae,2016,38(4):411-415.In Chinese with English abstract.
4. WANG Changyan,PEI Huaiteng,YU Xiaojuan.Different doses of pulmonary surfactant in treatment of neonatal respiratory distress syndrome[J].Chin J Woman Child Health Res,2015,26(2):264-268.In Chinese with English abstract.
5. WANG Xiaohu,JIANG Hong,NIU Shiping.Clinical study of different doses of calf pulmonary surfactant in the treatment of respiratory distress syndrome in late preterm infants[J].Chin J Neonatol,2014,29(1):43-45.In Chinese.
6. Jadad A R,Moore R A,Carroll D,et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary?[J].Control Clin Trials,1996,17(1):1-12.
7. Konishi M,Fujiwara T,Naito T,et al.Surfactant replacement therapy in neonatal respiratory distress syndrome. A multi-centre, randomized clinical trial: comparison of high- versus low-dose of surfactant TA[J].Eur J Pediatr,1988,147(1):20-25.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口